ArticleInvestigational new drugs2007

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).

Charles J Ryan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.